CHICAGO (PRWEB) April 12, 2018
Dracen Pharmaceuticals, Inc. announced today that two preclinical studies describing the immuno-metabolism and anti-cancer effects of its glutamine antagonist program will be presented April 17th during the American Association for Cancer Research annual meeting in Chicago.
The presentations will be made by two members of the Johns Hopkins Bloomberg~Kimmel Institute for Cancer. Details are as follows:
- Oral presentation from Robert Leone, MD, Instructor of Oncology, entitled: “Targeting glutamine metabolism as a means of enhancing anti-tumor T-cell responses” (Presentation #4963, April 17th, 3:20 pm, Rm w196)
- Poster presentation from Min-Hee Oh, PhD, entitled: “Targeting glutamine metabolism enhances tumor specific immunity by inhibiting the generation and function of suppressive myeloid cells” (Poster 4730, April 17th, 1-5 pm, Section 34)
The research was performed in the lab of Jonathan Powell, MD, PhD, the Associate Director of the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy and Professor of Oncology at the John Hopkins University School of Medicine. He is one of the Scientific founders of Dracen Pharmaceuticals.
About Dracen Pharmaceuticals
Dracen Pharmaceuticals, Inc. is a private biotech company developing proprietary anti-cancer drugs that target immuno-metabolism. Our lead glutamine antagonist, DRP-104, is advancing through preclinical development studies with the goal of initiating phase I clinical studies in the first half of 2019.